Phylogica (ASX: PYC) has formed a collaboration with Cubist Pharmaceuticals (NASDAQ: CBST), a US$3.57 billion market cap, to evaluate several of its antimicrobial Phylomers in models of multi-drug resistant bacterial infections.
The company hopes that its antimicrobial Phylomers will support Cubist’s ongoing work to discover and develop new antibiotics to address the growing global health threat of antibiotic resistance.
In its own assays, these antimicrobials have shown activity against multi-resistant isolates of Gramnegative, which are a major cause of deaths from hospital acquired infections of burn wounds.
The company’s proprietary Phylomer peptide libraries and screening methodologies are used to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.
These peptides are sourced from evolutionary diverse microbes and they represent a new class of biological therapeutics.
They display structural stability, specificity and affinity that give them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies.
Phylogica had recently patented an improvement to its Phylomer peptide platform that will allow more efficient screening of its library of billions of naturally occurring peptides and identify those with the highest potential to target disease proteins inside the cells.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.